Published online Nov 8, 2014. doi: 10.5409/wjcp.v3.i4.69
Revised: September 2, 2014
Accepted: October 23, 2014
Published online: November 8, 2014
Core tip: Nephrotic syndrome (NS) is the most common pediatric glomerular disease. Although outcomes are favorable, the treatment of complicated nephrotic syndrome can be challenging. Rituximab (RTX) offers a safe and effective alternative to current immunosuppressive therapies for complicated cases of NS. The best outcomes are seen in patients with steroid-dependent NS who have failed to respond to multiple therapies. However, the benefits of RTX therapy are limited in patients with steroid-resistant nephrotic syndrome. Successful RTX therapy induces prolonged remission and enables discontinuation of other medications without increasing the risk of infection and other adverse events.